Nasopharyngitis was cited in 20 studies from 19 published articles: Patients (13.55%, 729/5380) in the anti-IL-5 treatment group had a similar likelihood of suffering nasopharyngitis compared to those (15.45%, 734/475) in the placebo group (RR: 0.95, 95%CI: 0.86–1.04, P = 0.284, I2 = 11.4%). This evidence concerns the gene IL5 and nasopharyngitis.